Sheldon Breanna L, Olmsted Zachary T, Sabourin Shelby, Heydari Ehsaun, Harland Tessa A, Pilitsis Julie G
Department of Neuroscience and Experimental Therapeutics, Albany Medical College, Albany, NY 12208, USA.
Department of Neurosurgery, Albany Medical College, Albany, NY 12208, USA.
Brain Sci. 2022 Dec 16;12(12):1727. doi: 10.3390/brainsci12121727.
Central neuropathic pain (CNP) affects millions worldwide, with an estimated prevalence of around 10% globally. Although there are a wide variety of treatment options available, due to the complex and multidimensional nature in which CNP arises and presents symptomatically, many patients still experience painful symptoms. Pharmaceutical, surgical, non-invasive, cognitive and combination treatment options offer a generalized starting point for alleviating symptoms; however, a more customized approach may provide greater benefit. Here, we comment on the current treatment options that exist for CNP and further suggest the need for additional research regarding the use of biomarkers to help individualize treatment options for patients.
中枢性神经病理性疼痛(CNP)影响着全球数百万人,全球估计患病率约为10%。尽管有各种各样的治疗选择,但由于CNP产生和表现出症状的性质复杂且具有多维度性,许多患者仍然经历疼痛症状。药物、手术、非侵入性、认知和联合治疗选择为缓解症状提供了一个通用的起点;然而,更个性化的方法可能会带来更大的益处。在此,我们对目前存在的CNP治疗选择进行评论,并进一步表明需要对使用生物标志物以帮助为患者个体化治疗选择进行更多研究。